Arformoterol, a selective long-acting β2-adrenergic receptor agonist (LABA), is a critical therapeutic agent for respiratory conditions like chronic obstructive pulmonary disease (COPD). As the (R,R)-enantiomer of formoterol, it offers enhanced efficacy in bronchodilation with applications in nebulized solutions and combination therapies . This article provides a detailed analysis of the ​global Arformoterol buyer landscape, including supplier directories, regulatory trends, and procurement strategies to navigate this niche yet vital market. 1. Understanding Arformoterol: Applications and Market Context Arformoterol (CAS 67346-49-0) operates by relaxing airway muscles, making it a cornerstone for COPD management, including chronic bronchitis and emphysema . Its specificity for β2-adrenergic receptors (Kd: 2.9 nM) underpins its therapeutic value, with…